(MENAFN- ProactiveInvestors)
() has signed an exclusive distribution agreement with Medicare International Trading Limited.
This covers the sale of its EmbryoCellect in-vitro fertilisation kit in China Hong Kong and Macau.
China has one of the biggest in vitro fertilisation (IVF) markets in the world with approximately 300000 IVF cycles now being performed annually through around 300 clinics.
The largest Chinese clinic conducts over 20000 cycles annually which is more than the total for many countries.
Genetic testing is currently conducted by less than 20 clinics in China but the opportunity for the PGS market to grow is immense.
Hong Kong has approximately 13 clinics and conducts around 5000 IVF cycles annually. Macau has 3 clinics and conducts around 400 IVF cycles annually.
RHS is developing a network of international distributors with established sales channels into the IVF market.
It will also sell EmbryoCellect directly to customers in Australia and other regions where distributors are not engaged.
RHS has also established a Pre-implantation Genetic Screening (PGS) service business to provide access to EmbryoCellect to IVF clinics during their early stages of bringing the testing in-house or to clinics that prefer to outsource their testing.
Proactive Investors Australia is the market leader in producing news articles and research reports on ASX emerging companies with distribution in Australia UK North America and Hong Kong / China.
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.